跳至主要内容
临床试验/NCT00236678
NCT00236678终止2 期

A Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis Receiving PROCRIT� (Epoetin Alfa)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.0 个研究点目标入组 29 人开始时间: 2004年7月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
29
主要终点
To assess changes in fatigue in patients at least 18 years old with chronic rheumatoid arthritis (RA) and chronic anemia (Hb < 11.0 g/dL) due to ACD receiving weekly s.c. doses of PROCRIT versus placebo.

研究概览

简要总结

The purpose of this research study is to determine fatigue (tiredness) in subjects with chronic Rheumatoid Arthritis with chronic anemia. Fatigue in subjects who get PROCRIT will be compared to fatigue in subjects who get placebo (a medically inactive substance). The study will also evaluate hemoglobin levels (oxygen-carrying protein in red blood cells), safety, anemia related health concerns, vitality, arthritis related function and work productivity.

详细描述

PROCRIT is not approved for the treatment of anemia of chronic disease in rheumatoid arthritis patients.

Approximately 270 subjects will be participating in this trial, at approximately 25 centers in the United States. Patients will be eligible to participate in this study if hemoglobin (Hb) is <=11.0 g/dL. The hypothesis is that PROCRIT improves fatigue scores in rheumatoid arthritis patients with anemia of chronic disease. If a patient chooses to participate, he/she will be randomized to receive either PROCRIT or placebo on a weekly basis starting at 20,000 units per injection (up to a maximum of 40,000 units).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must have rheumatoid arthritis with chronic anemia. Patients must have signed an informed consent
  • women must be postmenopausal for at least one year, surgically sterile, or practicing an effective method of birth control, or have a negative serum pregnancy test
  • women must not be breast feeding during this study period.

排除标准

  • Uncontrolled hypertension
  • elective surgery, including joint replacement, anticipated to require transfusion during the extension study period
  • thromboembolic event during the double-blind study including acute myocardial infarction, cerebrovascular accident and/or transient ischemic attack
  • deep vein thrombosis and/or pulmonary embolism
  • uncontrolled psychiatric disease
  • planning to be enrolled in any other clinical trial during the course of this study

结局指标

主要结局

To assess changes in fatigue in patients at least 18 years old with chronic rheumatoid arthritis (RA) and chronic anemia (Hb < 11.0 g/dL) due to ACD receiving weekly s.c. doses of PROCRIT versus placebo.

次要结局

  • Hb response; changes in anemia associated health concerns; changes in vitality; changes in arthritis related function

研究者

相似试验